Azoramide - Moligand™, 10mM in DMSO , CAS No.932986-18-0

CAS: 932986-18-0 Cat. No.: A426981 Formule: C₁₅H₁₇ClN₂OS Poids moléculaire: 308.83

GRADE & PURITY Moligand™, 10mM in DMSO

Synonyms

CCG-267569 | BRD-K67416388-001-01-3 | N-[2-[2-(4-chlorophenyl)-1,3-thiazol-4-yl]ethyl]butanamide | SCHEMBL21523880 | Azoramide, >=98% (HPLC) | NCGC00484058-03 | s8304 | BCP23896 | NCGC00484058-01 | N-{2-[2-(4-chlorophenyl)-1,3-thiazol-4-yl]ethyl}butanamid

Storage

Store at -80°C

Shipped In

Dry ice packs + Cold packs

Specifications

Synonymes

CCG-267569 | BRD-K67416388-001-01-3 | N-[2-[2-(4-chlorophenyl)-1,3-thiazol-4-yl]ethyl]butanamide | SCHEMBL21523880 | Azoramide, >=98% (HPLC) | NCGC00484058-03 | s8304 | BCP23896 | NCGC00484058-01 | N-{2-[2-(4-chlorophenyl)-1,3-thiazol-4-yl]ethyl}butanamid

Spécifications et pureté

Moligand™, 10mM in DMSO

Mécanismes biochimiques et physiologiques

Modulator of unfolded protein response (UPR). Protects cells from ER stress by improving ER protein folding and activating ER chaperone capacity. Also improves ER calcium retention. Improves liver ER function, glucose homeostasis and glucose-stimulated in

Conditions de stockage de stockage

Store at -80°C

Expédié en

Dry ice packs + Cold packs

Ce produit nécessite l'expédition en chaîne froide. Les services terrestres et autres services économiques ne sont pas disponibles.

Grade

Moligand™

Type d'action

INHIBITOR

Noms et identifiants

• Sourires canoniques: CCCC(=O)NCCC1=CSC(=N1)C2=CC=C(C=C2)Cl
• IUPAC Name: N-[2-[2-(4-chlorophenyl)-1,3-thiazol-4-yl]ethyl]butanamide
• InChIKey: VYBFWKKCWTXCQX-UHFFFAOYSA-N
• INCHI: 1S/C15H17ClN2OS/c1-2-3-14(19)17-9-8-13-10-20-15(18-13)11-4-6-12(16)7-5-11/h4-7,10H,2-3,8-9H2,1H3,(H,17,19)
• Isomères SMILES: CCCC(=O)NCCC1=CSC(=N1)C2=CC=C(C=C2)Cl
• Poids moléculaire: 308.83
• Reaxy-Rn: 34161097
• Reaxys-RN_link_address: https://www.reaxys.com/reaxys/secured/hopinto.do?context=S&query=IDE.XRN=34161097&ln=

Taxonomic Classification

Taxonomy Tree

• Kingdom Organic compounds
  • Superclass Organoheterocyclic compounds
    • Classe Azoles
      • Subclass Thiazoles

• Kingdom: Organic compounds
• Superclass: Organoheterocyclic compounds
• Classe: Azoles
• Subclass: Thiazoles
• Intermediate Tree Nodes: Not available
• Direct Parent: 2,4-disubstituted thiazoles
• Alternative Parents: Chlorobenzenes N-acyl amines Aryl chlorides Heteroaromatic compounds Secondary carboxylic acid amides Azacyclic compounds Organonitrogen compounds Organochlorides Organic oxides Hydrocarbon derivatives Carbonyl compounds
• Molecular Framework: Aromatic heteromonocyclic compounds
• Substituents: 2,4-disubstituted 1,3-thiazole - Chlorobenzene - Halobenzene - Aryl chloride - Aryl halide - Monocyclic benzene moiety - Fatty acyl - Benzenoid - Fatty amide - N-acyl-amine - Heteroaromatic compound - Carboxamide group - Secondary carboxylic acid amide - Azacycle - Carboxylic acid derivative - Organonitrogen compound - Organooxygen compound - Organic nitrogen compound - Carbonyl group - Hydrocarbon derivative - Organic oxide - Organic oxygen compound - Organohalogen compound - Organochloride - Aromatic heteromonocyclic compound
• Description: This compound belongs to the class of organic compounds known as 2,4-disubstituted thiazoles. These are compounds containing a thiazole ring substituted at the positions 2 and 3.
• External Descriptors: Not available

Data sources

1. Djoumbou Feunang Y, Eisner R, Knox C, Chepelev L, Hastings J, Owen G, Fahy E, Steinbeck C, Subramanian S, Bolton E, Greiner R, and Wishart DS. ClassyFire: Automated Chemical Classification With A Comprehensive, Computable Taxonomy. Journal of Cheminformatics, 2016, 8:61.

DOI: 10.1186/s13321-016-0174-y

Propriétés chimiques et physiques

• Poids moléculaire: 308.800 g/mol
• XLogP3: 3.700
• Hydrogen Bond Donor Count: 1
• Hydrogen Bond Acceptor Count: 3
• Rotatable Bond Count: 6
• Exact Mass: 308.075 Da
• Monoisotopic Mass: 308.075 Da
• Topological Polar Surface Area: 70.200 Ų
• Heavy Atom Count: 20
• Formal Charge: 0
• Complexity: 308.000
• Isotope Atom Count: 0
• Defined Atom Stereocenter Count: 0
• Undefined Atom Stereocenter Count: 0
• Defined Bond Stereocenter Count: 0
• Undefined Bond Stereocenter Count: 0
• The total count of all stereochemical bonds: 0
• Covalently-Bonded Unit Count: 1

Références

1. Fengying Dai, Kepeng Lv, Bo Zhang, Junqiang Zhao, Shaoteng Wang, Ke Lan, Yiping Zhao, Xiaolei Zhang, Bohong Kan.  (2023)  Overcoming the structure deficiency of nanodrug coated with tannic acid shell through phenolic hydroxyl protection strategy for Alzheimer's disease combination treatment.  Biomaterials Advances,      [PMID:37827021] [10.1016/j.bioadv.2023.213651]

Application Protocols

No tested applications or protocols are provided in the Product Data for this item.

General handling for small‑molecule stock solutions:

• Allow vial to equilibrate to room temperature in a desiccated environment before opening to avoid moisture condensation.
• Prepare a concentrated DMSO stock (e.g., 10–50 mM) based on the molecular weight on the CoA; vortex and, if needed, sonicate briefly to aid dissolution.
• Sterile filter (0.22 μm PTFE) if sterility is required and the compound is filter‑stable.
• Aliquot into single‑use portions to avoid repeated freeze–thaw. Record solvent, concentration, and date.

Assay use (general):

• Dilute the stock into assay buffer/media keeping vehicle ≤ assay tolerance (commonly ≤0.5–1% DMSO).
• Inspect for precipitation/turbidity; if present, adjust solvent percentage or pre‑solubilize with compatible co‑solvent.
• Include vehicle controls and, when applicable, benchmark controls.

Biological Roles

Item-specific biological targets, modes of action, or pathways are not included in the Product Data. The following are general considerations for small molecules used in research. No medical or clinical claims are made.

• Small molecules in screening libraries can act as chemical probes to modulate enzymes, receptors, transporters, or cellular pathways in a reversible and dose‑dependent manner.
• Appropriate use includes establishing structure–activity relationships (SAR), profiling selectivity across related target families, and conducting orthogonal assays to confirm on‑target activity.
• It is essential to evaluate assay interference (e.g., fluorescence quenching, redox cycling, aggregation) and to run counter‑screens to deconvolute non‑specific effects.
• For cellular studies, confirm permeability, efflux susceptibility, and metabolic stability (microsomes/hepatocytes) as these impact observed potency.
• If literature suggests a role in a specific pathway for this named compound, verify the lot’s identity and reproduce key controls before drawing mechanistic conclusions.

Please consult peer‑reviewed literature corresponding to the CAS/CID for putative biological roles and validate experimentally under your lab conditions.

Buffer Applications

This product is a discrete small molecule and is not a buffering agent. No pKa or buffering capacity data are provided in the Product Data.

• Not typically used to prepare buffer systems or to control pH.
• If the compound must be formulated in aqueous media, use a separate, established buffer (e.g., PBS, HEPES, Tris) suitable for your assay, and dissolve the compound in a compatible co‑solvent (often DMSO) before dilution into the buffer.
• Verify that the final vehicle concentration and buffer components do not cause precipitation or assay interference.

Green Alternatives

Because this listing is for a discrete small molecule (not a reaction solvent or process auxiliary), “green alternatives” primarily concern greener choices for handling and analysis rather than alternatives to the compound itself.

Greener handling considerations (general):

• Prefer water‑miscible, lower‑toxicity solvents when possible (e.g., ethanol) and minimize DMSO/DMF/NMP volumes. Validate solubility and assay performance.
• For chromatography, use ACN–water gradients instead of halogenated solvents when feasible; consider supercritical CO2 (SFC) for purification to reduce solvent use.
• Optimize micro-scale assays and high-concentration stocks to reduce solvent consumption and waste.

Illustrative comparison for stock preparation (general):

• DMSO: Excellent solvency; higher EHS burden; widely accepted in screening.
• Ethanol: Greener profile; may not dissolve hydrophobic compounds as well; potential biological interference at higher %.
• 2‑Propanol: Moderate solvency; easier handling; check assay tolerance.

Waste minimization:

• Consolidate compatible organic wastes; avoid halogenated solvents unless required.
• Use closed containers and cold storage to limit solvent volatilization and energy use via fewer re-preparations.

Pharmaceutical Uses

No pharmacopeial status, excipient role, or formulation guidance is provided for this item. This product is supplied strictly for research use only and is not intended for human or veterinary use.

General research‑only context for small molecules:

• May serve as a reference compound in preclinical discovery, screening, or mechanistic studies.
• If formulation for in vivo research is contemplated, develop appropriate vehicle systems (e.g., PEG400/saline, Captisol, or co‑solvent systems) and confirm stability, homogeneity, and tolerability under institutional guidelines. These steps are user‑responsibility and outside the scope of this listing.
• No claims are made regarding GMP status, clinical applicability, or regulatory filings.

Always consult internal regulatory and EHS teams before any use beyond basic laboratory research.

Physical Properties

Item-specific physicochemical specifications are not included in this listing. Do not assume values for critical parameters.

• Appearance: Not specified for this item; refer to CoA/Spec Sheet.
• Melting point (MP): Not specified for this item; refer to CoA/Spec Sheet.
• Boiling point (BP): Not typically applicable for a complex, potentially non-volatile small molecule; item-specific value not provided.
• Density: Not specified for this item; refer to CoA/Spec Sheet.
• Solubility: Not specified for this item; refer to CoA/Spec Sheet. Practical note: for small-molecule library members, initial dissolution screening commonly starts with DMSO, then expands to DMF, MeOH, EtOH, or aqueous buffers with co-solvent if permitted by your assay.
• logP / logD: Not specified for this item; refer to CoA/Spec Sheet.
• pKa: Not specified for this item; refer to CoA/Spec Sheet.
• Refractive index: Not applicable for solids; otherwise not specified.

General guidance (non-item-specific):

• If the compound is hydrophobic, expect higher solubility in polar aprotic solvents (DMSO, DMF) than in water; confirm experimentally.
• For analytical characterization, LC–MS and 1H/13C NMR in appropriate deuterated solvents (e.g., DMSO‑d6, CDCl3, CD3OD) are typical; select based on observed solubility.

Quality and Grades

• Grade/Purity: Not specified for this item; refer to CoA/Spec Sheet. The CoA will provide the assay method (e.g., HPLC area %, qNMR) and any impurity profile used for lot release.
• Typical expectations for small‑molecule library compounds (general, not item-specific):
  • Analytical verification: Identity by LC–MS and/or NMR; purity by HPLC/UPLC. Some lots may include residual solvent analysis and water content (KF).
  • Form: Neat solid or pre‑aliquoted DMSO solution. Verify form and concentration on label/CoA before use.
  • Chromatographic grade claims (if present): Indicate low non-volatile residue and UV background appropriate for analytical applications; none are specified here.
• Stabilizers/antioxidants: Not specified for this item; refer to CoA/Spec Sheet. If stabilizers are used, note implications for bioassays (e.g., baseline activity, UV absorbance).

Recommendations:

• For bioassays, confirm purity and identity in-house (rapid LC–MS check) upon receipt, especially when working near potency thresholds.
• Record lot number in all data to ensure traceability. If orthogonal purity measurements are critical (e.g., for SAR), request or generate qNMR.

Reaction and Applications

This product is offered as a research small molecule and is not primarily intended as a synthetic reagent. No item‑specific reactivity data or application notes are provided in the Product Data.

Potential research applications (general, non-item-specific):

• Reference standard / tool compound: Use as a defined chemical entity in screening cascades, target validation experiments, or phenotypic assays. Ensure identity/purity via LC–MS before critical studies.
• Assay development: Establish dynamic range, signal window, and assay robustness (Z’ factor) by including the compound as a positive/negative control where appropriate.
• Mechanistic studies: If a literature mechanism or pathway association exists, confirm with orthogonal assays and counter-screens to exclude assay interference.

Good practices:

• Prepare fresh stocks or aliquot to avoid multiple freeze–thaw cycles.
• Document solvent, concentration, and final vehicle % in all experiments.
• Confirm stability under assay conditions (time, temperature, light, pH) by periodic analytical checks (LC–UV/MS).

If you intend to use this compound as a building block or reagent, first verify functional groups and compatibility from a verified structure (CoA/SDS) and consult synthetic sections below accordingly.

Reaction Conditions

Not typically applicable: this listing is for a discrete research small molecule, not a reagent. No item-specific reaction condition data are provided.

If you plan to derivatize or conjugate the compound (general guidance):

• Solvents: Choose based on solubility (often DMSO, DMF, MeOH, or ACN). Dry, oxygen‑free conditions may be required depending on functional groups.
• Temperatures: Start at ambient; adjust as needed once stability is confirmed by TLC or LC–MS. Avoid prolonged heating until thermal stability is established.
• Catalysts/bases/acids: Select only after verifying functional groups; run small‑scale trials and monitor for decomposition.
• Workup/purification: Employ flash chromatography or preparative LC. For base/acid‑sensitive molecules, use neutral silica or reversed‑phase methods.

Because the exact structure is not provided here, do not generalize named reaction conditions to this compound without first confirming compatibility.

Safety and Handling

Safety information specific to this item is not provided in the Product Data. Always consult the official SDS for your received lot before use.

• Research use only: Yes (per listing). Not for human or animal therapeutic or diagnostic use.
• GHS/CLP classification: Not specified for this item; refer to SDS.
• Signal word / Pictograms / H‑statements: Not specified for this item; refer to SDS.

General laboratory precautions (good practice):

• PPE: Lab coat, safety glasses, and suitable chemical-resistant gloves. Consider handling in a chemical fume hood, particularly during weighing, dissolution in volatile solvents, or if dust generation is possible.
• Avoid: Inhalation of dust/aerosols, skin and eye contact, and ingestion. Prevent environmental release; dispose of according to institutional and regulatory requirements.
• First aid (overview): In case of skin or eye contact, rinse with water for at least 15 minutes and seek medical attention as needed. If inhaled, move to fresh air. If swallowed, rinse mouth; obtain medical attention. Always follow SDS instructions.
• Incompatibilities: Unknown for this specific item; as a precaution, avoid strong oxidizers and strong acids/bases until stability/compatibility are confirmed.
• Thermal/photostability: Store as directed (−80 °C). Minimize repeated freeze–thaw and protect from moisture and light unless data indicate stability.

Solvent Selection

No item‑specific solubility profile is provided. The guidance below reflects common practice for dissolving library small molecules for screening and analytical work.

• Primary stock solvent: DMSO is typically the first choice due to broad solubilizing power and biological assay compatibility at ≤0.5–1% v/v final concentration.
• Secondary options: DMF, NMP, acetone, acetonitrile, methanol, ethanol. Test sequentially and document exact solvent and concentration.
• Aqueous work: If aqueous compatibility is needed, prepare a concentrated DMSO stock (e.g., 10–50 mM) and dilute into buffer while maintaining DMSO below your assay’s tolerance. Use surfactant (e.g., 0.01–0.05% Tween‑20) if precipitation is observed and assay permits.
• pH adjustments: If the compound has ionizable groups (unknown here), modest pH shifts can improve solubility. Validate chemical stability vs. pH by LC.
• Analytical solvents: For LC–MS, water/acetonitrile (0.1% formic acid) or water/methanol systems are standard; confirm UV cutoff and ionization response.

Quick comparison (general):

• DMSO: Highest solvency; biologically tolerated at low %; hygroscopic.
• DMF/NMP: Strong solvents; consider toxicity and downstream compatibility.
• MeOH/EtOH: Easier to remove; lower solvency for hydrophobics.
• ACN: LC‑compatible; moderate solvency.

Always verify absence of precipitation after dilution into assay media.

Storage and Reconstitution

Item-specific storage conditions are provided below; additional reconstitution details should be confirmed on the CoA for your lot.

• Storage conditions (product data): Store at −80 °C.
• Shipping (product data): Shipped on dry ice packs + cold packs to maintain low temperature.
• Form: Not specified for this item; refer to CoA/Spec Sheet (solid vs. solution, mass, concentration, and any stabilizers).

Best practices:

• If supplied as a solid, store in a tightly sealed, desiccated container under inert gas if possible. Equilibrate to room temperature before opening to prevent condensation. Reseal promptly.

• If supplied in DMSO solution, keep at −80 °C and minimize freeze–thaw by aliquoting. Avoid frost‑free freezers that cycle temperature.

• Protect from light and moisture unless stability data indicate tolerance.

• For reconstitution, use an anhydrous solvent (commonly DMSO) and calculate concentration using the molecular weight reported on the CoA. Mix thoroughly; brief sonication may help.

• Document preparation details (solvent, concentration, date, lot) on the vial and in your ELN. Periodically re‑assess integrity by LC–MS if stored long term.

• Expiration/retention: Follow CoA guidance; if absent, implement internal re‑testing intervals based on risk and use pattern.

Structure and Identity

Brief overview: Azoramide is listed in our small-molecule/compound library category. Limited item-specific structural data are provided in this listing; consult the CoA/Spec Sheet for definitive identifiers.

• SKU: A426981
• Product name: Azoramide
• CAS: 932986-18-0 (literature identifier for Azoramide)
• PubChem CID: 7518316 (literature)
• InChIKey (product data): 391441 (as supplied in Product Data)
• SMILES: Not specified for this item; refer to CoA/Spec Sheet.
• Molecular formula: Not specified for this item; refer to CoA/Spec Sheet.
• Molecular weight: Not specified for this item; refer to CoA/Spec Sheet.

Structural description (general):

• Item-specific structural features (ring systems, functional groups, stereochemistry) are not provided in the Product Data. For researchers needing exact 2D/3D depictions and tautomer/stereochemical details, please consult the SDS/CoA or authoritative databases corresponding to the CAS and CID listed above.

Notes:

• When preparing stock solutions, verify the exact identity and any salt/hydrate form on the CoA to calculate molarity correctly.
• If using structure-based design or docking, obtain a vendor CoA/SDF file or retrieve a verified structure file from a trusted database and cross-check with the lot CoA.

Synthetic Utility

This product is offered as a finished small molecule rather than a synthetic building block. No functional group annotation or reactivity profile is provided in the Product Data.

General guidance if synthetic modification is intended:

• Obtain the verified structure (from CoA/SDS) and assess the presence of modifiable handles (e.g., aryl halides, amines, carboxyls, heterocycles) to plan derivatization.
• Use orthogonal protection/deprotection strategies when introducing tags or probes (e.g., biotin, fluorophores), and confirm that modifications do not disrupt intended activity.
• For SAR campaigns, maintain a consistent core scaffold while varying substituents to explore electronic and steric effects; employ parallel synthesis and rapid LC–MS QC.

Without confirmed functional groups, no specific named reactions or transformations can be responsibly recommended for this item.

Target Specificity

No target, pathway, or binding data are provided for this item in the Product Data.

• Target/Pathway: Not specified for this item; refer to CoA/Spec Sheet and primary literature.
• Selectivity profile: Not specified for this item; refer to peer‑reviewed studies if available for the given CAS/CID.

If used as a tool compound, determine specificity via:

• Cross‑screening against related targets.
• Orthogonal biochemical and cell‑based assays.
• Counter‑screens for assay interference and off‑target liabilities.